Tatton Consulting supported Oxford-based T-cell receptor discovery company Exogene in its successful application to Advancing precision medicine: Round 2, which was awarded £529,037 by Innovate UK for the project ST TCR – Unlocking the discovery of novel shared targets and T-cell receptors for precision cancer therapies. The project’s total Innovate UK grant across all partners was £667,498.
About the funded R&D project
Most T-cell receptor therapies are developed against targets found in individual patients, which constrains how widely any one therapy can be used. This project works on the discovery of shared targets, present across multiple patients, and the receptors that recognise them. Shared targets are the route to precision cancer therapies that can be manufactured once and used across a patient population rather than built individually.
Award details
- Grant to Exogene: £529,037
- Total project grant (all partners): £667,498
- Competition: Advancing precision medicine: Round 2
- Competition year: 2023/24
- Project: ST TCR – Unlocking the discovery of novel shared targets and T-cell receptors for precision cancer therapies
- Sector: Oncology / biotechnology
- Independent verification: Innovate UK funded projects transparency dataset (UKRI), published 10 August 2026
Tatton Consulting supported the competitive grant application. The award value, competition and project title above are taken from Innovate UK’s published record of funded projects.
See all Innovate UK awards Tatton Consulting has supported on our grant successes page.
